Investment Thesis
A high-stakes, capital-efficient opportunity in a proven drug class — where chemistry platform IP creates defensible value at every development milestone.
A $100B+ Market With a Structural Resistance Problem
Nucleoside therapeutics generate over $15B annually in oncology alone, yet their reach is capped by resistance mechanisms that the field has not systematically solved. Sunom's SNM chemistry is positioned to capture share across resistant solid tumors and high-value antiviral indications — not by competing in an established market, but by opening new patient populations where no effective therapy exists.
Platform-based deals in nucleoside and small-molecule oncology have commanded premium valuations at every stage. The comparable transaction landscape below reflects what strategic acquirers and institutional investors have paid for assets at comparable preclinical and Phase 1 stages.
What We're Building Toward
- IND clearance as the primary Series A catalyst and valuation inflection
- Oncology partnering or co-development at or post-IND for bread-and-butter Solid Tumor indications
- BARDA / governmental procurement pathway for SNM-AV antiviral indication
- Phase 1 PoC data as the primary value-creation event before Series B or strategic out-licensing
Why Now?
-
GEM resistance is clinically proven
No approved drugs address multiple resistance simultaneously
-
Regulatory tailwinds
FDA Project Optimus, accelerated pathways for resistance-targeting agents
-
Pandemic preparedness priority
BARDA, CEPI prioritize broad-spectrum antivirals
Why Sunom?
-
Unique chemistry IP
Composition-of-matter patents covering novel SNM modifications
-
Team with skin in the game
Co-founders with prior nucleoside IP at Moderna + NASDAQ IPO operator
-
Dual optionality
Single platform de-risks via two independent value streams
Ready to discuss the opportunity?
We are raising a Seed round to complete IND-enabling studies and position the company for the next major inflection point.